arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Supernus Pharmaceuticals, Inc.

SUPN Health Care Biotechnology: Pharmaceutical Preparations
$40.70
▼ -1.2% Today
as of Oct 23, 16:52 ET
Last 30 days -1.90% Sep 14 → Oct 23
$37.34 $39.29 $41.24 $43.19 $45.14 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$41.68
High
$41.94
Low
$39.97
Volume
$1M
Avg Vol
$780,584
Mkt Cap
$2.5B
P/E (TTM)
—
Beta
—
52w High
$59.68
52w Low
$37.54
Div Yield
—
Shares Out
$58M

Recent Press Releases & News last 60 days · 8 items

Oct 22 · 13:00 Zacks
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Oct 21 · 23:45 PR GlobeNewswire
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Oct 19 · 12:30 PR GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
▸ Show all 8 press releases & news Free account →

SUPN earnings at a glance

Supernus Pharmaceuticals, Inc. (SUPN) is scheduled to report earnings on Tuesday, November 3, 2026 — in 10 days. Analysts expect earnings per share of $0.66, compared with $0.46 in the same quarter last year (+43%). The options market is pricing a move of about ±9.4% after the report, a range of roughly $36.89 to $44.51 from today's $40.70. Over its last 6 reports the stock rose the next day 4 times and fell 2, moving ±8.1% on average; after the most recent report on Aug 4, 2026 it moved +3.1%. That means options currently expect more movement than SUPN has typically delivered. SUPN beat the consensus EPS estimate in 6 of its last 6 reported quarters. Implied volatility is currently 53%. The share price of $40.70 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$38
$60
14% of range
Avg surprise (last 6)
+143.9%
Avg reaction (last 6)
+0.7%
67% positive
Latest IV / EM
53%
EM ±9.4% · $44 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.29$-0.02$0.25$0.51$0.78 Actual $0.29Actual $-0.02Actual $-0.29Actual $0.36Actual $0.69Actual $0.28Est $0.26Actual $0.78Est $0.34Actual $0.46Est $0.33Actual $0.75Est $0.14Actual $0.45Est $0.14Actual $0.39Est $0.30 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-58M$14M$86M$158M$230M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 4, 2026Jun/2026 $0.39 $0.30 +30.0% -61.5% +3.1% earnings
Tue May 5, 2026Mar/2026 $0.45 $0.14 +221.4% +60.7% +4.6% earnings
Tue Feb 24, 20268K 2026-02-24 $0.75 $0.14 +435.7% — +5.7% earnings
Tue Nov 4, 2025Sep/2025 $0.46 $0.33 +39.4% — -17.4% earnings
Tue Aug 5, 2025Jun/2025 $0.78 $0.34 +129.4% — +13.1% earnings
Tue May 6, 2025Mar/2025 $0.28 $0.26 +7.7% — -4.6% earnings
Mon Sep 30, 2024Sep 2024 $0.69 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.36 — — — — financials
Sun Mar 31, 2024Mar 2024 — — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.29 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.02 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.29 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Tue Nov 3, 2026Sep/2026OTHER $0.66$0.46 +43.5%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$219M$208M—$192M$165M$150M—$176M
Cost of revenue$34M$23M—$19M$17M$16M—$18M
Gross profit————————
Operating income$-58M$-8M—$-60M$12M$-10M—$41M
Net income$-58M$-2M—$-45M$22M$-12M—$38M
EPS (diluted)$-1.01$-0.04—$-0.80$0.40$-0.21—$0.69

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$180M$185M$128M$151M$145M$116M$69M$32M
Inventory$107M$111M$112M$107M$44M$49M$54M$64M
Total current assets$723M$732M$644M$594M$739M$688M$686M$640M
Total assets$1.43B$1.50B$1.45B$1.42B$1.38B$1.35B$1.37B$1.34B
Long-term debt————————
Total liabilities$397M$424M$391M$370M$319M$317M$332M$336M
Total equity$1.03B$1.08B$1.06B$1.05B$1.06B$1.03B$1.04B$1.01B

Implied volatility — last 90 days

25%70%115%160%205% Jun 07 — IV 45% · EM ±6.3%Jun 08 — IV 43% · EM ±5.7%Jun 09 — IV 54% · EM ±6.8%Jun 10 — IV 42% · EM ±5.0%Jun 11 — IV 48% · EM ±5.3%Jun 12 — IV 45% · EM ±4.6%Jun 19 — IV 50% · EM ±11.2%Jun 22 — IV 37% · EM ±7.8%Jun 23 — IV 34% · EM ±7.0%Jun 24 — IV 43% · EM ±8.6%Jun 25 — IV 25% · EM ±5.0%Jun 26 — IV 41% · EM ±7.8%Jun 29 — IV 48% · EM ±8.5%Jun 30 — IV 39% · EM ±6.8%Jul 01 — IV 47% · EM ±7.9%Jul 06 — IV 61% · EM ±8.5%Jul 07 — IV 54% · EM ±7.2%Jul 08 — IV 54% · EM ±6.7%Jul 09 — IV 60% · EM ±7.1%Jul 10 — IV 64% · EM ±7.1%Jul 15 — IV 122% · EM ±7.2%Jul 20 — IV 55% · EM ±13.0%Jul 21 — IV 60% · EM ±14.0%Jul 22 — IV 58% · EM ±13.3%Jul 23 — IV 56% · EM ±12.5%Jul 24 — IV 61% · EM ±13.5%Jul 27 — IV 67% · EM ±14.0%Jul 28 — IV 65% · EM ±13.3%Jul 29 — IV 66% · EM ±13.3%Jul 30 — IV 55% · EM ±10.8%Jul 31 — IV 66% · EM ±12.6%Aug 03 — IV 66% · EM ±11.6%Aug 04 — IV 75% · EM ±12.9%Aug 05 — IV 49% · EM ±8.2%Aug 06 — IV 70% · EM ±11.3%Aug 12 — IV 91% · EM ±11.4%Aug 24 — IV 44% · EM ±9.2%Aug 25 — IV 45% · EM ±9.1%Aug 26 — IV 46% · EM ±9.1%Aug 31 — IV 55% · EM ±9.8%Sep 10 — IV 84% · EM ±10.0%Sep 11 — IV 90% · EM ±10.0%Sep 14 — IV 118% · EM ±9.9%Sep 17 — IV 205% · EM ±8.6%Sep 21 — IV 48% · EM ±10.1%Sep 22 — IV 46% · EM ±9.5%Sep 23 — IV 52% · EM ±10.5%Sep 24 — IV 52% · EM ±10.3%Sep 25 — IV 52% · EM ±10.0%Sep 28 — IV 53% · EM ±9.4%

Sector peers

KLRA
Kailera Therapeutics, Inc.
$2.4B $12.85-0.5%
LQDA
Liquidia Corporation
$2.4B $42.65+9.8%
MBX
MBX Biosciences, Inc.
$2.6B $48.50-10.1%
BHC
Bausch Health Companies Inc.
$2.3B $6.44-0.2%
HRMY
Harmony Biosciences Holdings, Inc.
$2.3B $36.13-5.7%
PBH
Prestige Consumer Healthcare Inc.
$2.3B $47.80-0.2%

SUPN earnings FAQ

When is SUPN's next earnings date?

Supernus Pharmaceuticals, Inc. is expected to report on November 3, 2026.

What is SUPN's expected move for earnings?

Options currently price a move of about ±9.4%, or $3.81 per share either way from $40.70.

How does SUPN stock usually react to earnings?

Across the last 6 reports the average next-day move was ±8.1%, up 4 times and down 2 times.

What EPS are analysts expecting from Supernus Pharmaceuticals, Inc.?

The consensus estimate is $0.66 per share, versus $0.46 a year ago.

What is SUPN's implied volatility?

SUPN's at-the-money implied volatility is about 53% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in